MedTrace Logo

Mono-menotropins Versus rFSH Protocol on Embryo Quality

NCT02418533 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2020-08-12

No results posted yet for this study

Summary

This study is for couples pursuing in vitro fertilization (IVF) with preimplantation genetic screening (PGS) of embryos to achieve pregnancy. The objective of this clinical trial is to study the effect of mono-menotropins for COS versus recombinant follicle stimulating hormone (rFSH) on cleavage-stage and blastocyst embryo quality after IVF. Embryo quality parameters include conventional embryo grade, early embryo viability assessment (Eeva) time-lapse parameters, and chromosomal aneuploidy rates after PGS.

This pilot study is expected to significantly contribute to optimization of treatment regimens and stimulation protocols to optimize embryo quality.

Conditions

Interventions

DRUG

menotropin

Menopur is used for controlled ovarian stimulation (COH)

DRUG

Recominant Follicle Stimulating Hormone (rFSH)

Gonal-f is used for controlled ovarian stimulation (COH)

Sponsors & Collaborators

  • Main Line Fertility Center

    lead OTHER

Principal Investigators

  • Michael J Glassner, MD · Main Line Fertility

  • Sharon H Anderson, PhD · Main Line Fertility

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-04-30
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02418533 on ClinicalTrials.gov